Search results
Results from the WOW.Com Content Network
Discoid lupus erythematosus (DLE) is an uncommon autoimmune disease of the basal cell layer of the skin. It occurs in humans [1] and cats, more frequently occurring in dogs. It was first described in dogs by Griffin and colleagues in 1979. [2] [3] DLE is one form of cutaneous lupus erythematosus (CLE). DLE occurs in dogs in two forms: a ...
Discoid lupus erythematosus is the most common type of chronic cutaneous lupus (CCLE), an autoimmune skin condition on the lupus erythematosus spectrum of illnesses. [ 1 ] [ 2 ] It presents with red, painful, inflamed and coin-shaped patches of skin with a scaly and crusty appearance, most often on the scalp, cheeks, and ears.
Sometimes symptoms are characterized by lymphadenopathy, which involves loss of appetite, weakness, fever, and in rare cases, sepsis. [9] Pemphigus foliaceus is the most common autoimmune skin disease in dogs, making up around one-third of all canine autoimmune disorders. [16] This disease usually affects areas of the ears and face. [9]
The Centers for Disease Control and Prevention estimates that more than 200,000 people in the U.S. have lupus, though the Lupus Foundation of America puts the total much higher: roughly 1.5 ...
It is a rare disease in dogs, with cats seven to ten times more likely to be infected. The disease in dogs can affect the lungs and skin, but more commonly the eye and central nervous system. [20] Ringworm is a fungal skin disease that in dogs is caused by Microsporum canis (70%), Microsporum gypseum (20%), and Trichophyton mentagrophytes (10% ...
The disease impacts about 1.5 million Americans, but women are nine times more likely to develop lupus than men. And the cause of lupus has largely remained a mystery—until now.
Chilblain lupus erythematosus is characterized by a rash that primarily affects acral surfaces that are frequently exposed to cold temperatures, such as the toes, fingers, ears, and nose. The rash is defined by oedematous skin, nodules , and tender plaques with a purple discoloration.
The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...